Local News

FDA Extends Protection For Salix Drug

Posted August 29, 2006

— Salix Pharmaceuticals'

protection against generic competition for its ulcerative colitis drug for young people ages 5-17 has been extended through Jan. 8, 2007, by the Food and Drug Administration.

Salix had sought the additional marketing exclusivity for Colazal in June.


Please with your WRAL.com account to comment on this story. You also will need a Facebook account to comment.

Oldest First
View all